1587 related articles for article (PubMed ID: 21700325)
1. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.
Mazzulli JR; Xu YH; Sun Y; Knight AL; McLean PJ; Caldwell GA; Sidransky E; Grabowski GA; Krainc D
Cell; 2011 Jul; 146(1):37-52. PubMed ID: 21700325
[TBL] [Abstract][Full Text] [Related]
2. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
3. Glucocerebrosidase deficiency promotes release of α-synuclein fibrils from cultured neurons.
Gegg ME; Verona G; Schapira AHV
Hum Mol Genet; 2020 Jun; 29(10):1716-1728. PubMed ID: 32391886
[TBL] [Abstract][Full Text] [Related]
4. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
[TBL] [Abstract][Full Text] [Related]
5. Glucocerebrosidase dysfunction in neurodegenerative disease.
Brooker SM; Krainc D
Essays Biochem; 2021 Dec; 65(7):873-883. PubMed ID: 34528667
[TBL] [Abstract][Full Text] [Related]
6. Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.
Yap TL; Gruschus JM; Velayati A; Westbroek W; Goldin E; Moaven N; Sidransky E; Lee JC
J Biol Chem; 2011 Aug; 286(32):28080-8. PubMed ID: 21653695
[TBL] [Abstract][Full Text] [Related]
7. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease.
Magalhaes J; Gegg ME; Migdalska-Richards A; Doherty MK; Whitfield PD; Schapira AH
Hum Mol Genet; 2016 Aug; 25(16):3432-3445. PubMed ID: 27378698
[TBL] [Abstract][Full Text] [Related]
8. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM
Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608
[TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
Blanz J; Saftig P
J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
[TBL] [Abstract][Full Text] [Related]
10. Measurement of GCase Activity in Cultured Cells.
Shojima Y; Ogata J; Tsunemi T; Imai Y; Hattori N
Methods Mol Biol; 2021; 2322():47-52. PubMed ID: 34043191
[TBL] [Abstract][Full Text] [Related]
11. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.
Kumar M; Srikanth MP; Deleidi M; Hallett PJ; Isacson O; Feldman RA
Hum Mol Genet; 2023 May; 32(11):1888-1900. PubMed ID: 36752535
[TBL] [Abstract][Full Text] [Related]
12. Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models.
Xu YH; Sun Y; Ran H; Quinn B; Witte D; Grabowski GA
Mol Genet Metab; 2011 Apr; 102(4):436-47. PubMed ID: 21257328
[TBL] [Abstract][Full Text] [Related]
13. Loss of β-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cells.
Dermentzaki G; Dimitriou E; Xilouri M; Michelakakis H; Stefanis L
PLoS One; 2013; 8(4):e60674. PubMed ID: 23580063
[TBL] [Abstract][Full Text] [Related]
14. A lysosomal lair for a pathogenic protein pair.
Dawson TM; Dawson VL
Sci Transl Med; 2011 Jul; 3(91):91ps28. PubMed ID: 21753118
[TBL] [Abstract][Full Text] [Related]
15. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
Wong YC; Krainc D
Mov Disord; 2016 Nov; 31(11):1610-1618. PubMed ID: 27619775
[TBL] [Abstract][Full Text] [Related]
16. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
Johnson PH; Weinreb NJ; Cloyd JC; Tuite PJ; Kartha RV
Mol Genet Metab; 2020 Feb; 129(2):35-46. PubMed ID: 31761523
[TBL] [Abstract][Full Text] [Related]
17. Viable neuronopathic Gaucher disease model in Medaka (Oryzias latipes) displays axonal accumulation of alpha-synuclein.
Uemura N; Koike M; Ansai S; Kinoshita M; Ishikawa-Fujiwara T; Matsui H; Naruse K; Sakamoto N; Uchiyama Y; Todo T; Takeda S; Yamakado H; Takahashi R
PLoS Genet; 2015 Apr; 11(4):e1005065. PubMed ID: 25835295
[TBL] [Abstract][Full Text] [Related]
18. Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.
Naito Y; Sakamoto S; Kojima T; Homma M; Tanaka M; Matsui H
SLAS Discov; 2023 Oct; 28(7):344-349. PubMed ID: 37369311
[TBL] [Abstract][Full Text] [Related]
19. Structural features of membrane-bound glucocerebrosidase and α-synuclein probed by neutron reflectometry and fluorescence spectroscopy.
Yap TL; Jiang Z; Heinrich F; Gruschus JM; Pfefferkorn CM; Barros M; Curtis JE; Sidransky E; Lee JC
J Biol Chem; 2015 Jan; 290(2):744-54. PubMed ID: 25429104
[TBL] [Abstract][Full Text] [Related]
20. The effect of mutant GBA1 on accumulation and aggregation of α-synuclein.
Maor G; Rapaport D; Horowitz M
Hum Mol Genet; 2019 Jun; 28(11):1768-1781. PubMed ID: 30615125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]